Description
The abstract identifies rare protective variants in APOE and RELN genes but doesn’t explain the specific molecular mechanisms by which these variants delay cognitive impairment. Understanding these mechanisms is critical for developing targeted therapeutics that could replicate these natural protective effects.
Gap type: unexplained_observation Source paper: Protective genetic variants against Alzheimer’s disease. (2025, Lancet Neurol, PMID:40409316)
Resolution criteria
Resolution requires: (1) Biochemical assays (co-IP, pull-down) identifying the specific molecular interactions through which APOE or RELN protective variants alter disease-related pathways (A-beta binding, synaptic signaling, or tau phosphorylation), with >=2-fold difference in activity compared to risk variants; (2) Cellular validation in iPSC-derived neurons or organoids from protective variant carriers vs risk variant carriers, demonstrating >=50% reduction in a disease-relevant phenotype (e.g., A-beta secretion, tau aggregation, or synaptic loss); (3) Mechanistic tracing: downstream pathway activation states (phosphorylation, localization, expression) that differ between protective and risk variants and directly explain the protection phenotype. Variant association without mechanistic pathway dissection is insufficient.